ライフサイエンスコーパス: chemoprevention

1 erations and are thus key targets for cancer chemoprevention.

2 n the increasingly important field of cancer chemoprevention.

3 eillance with (n = 173) or without (n = 831) chemoprevention.

4 rker of gastric cancer risk and a target for chemoprevention.

5 the promising targets for cancer metastasis chemoprevention.

6 adherent children and those randomized to no chemoprevention.

7 children randomized to chemoprevention or no chemoprevention.

8 rgets for pancreatic cancer treatment and/or chemoprevention.

9 been proven to be an effective strategy for chemoprevention.

10 aluation elucidate their role in dietary CRC chemoprevention.

11 this setting and may represent a target for chemoprevention.

12 , and better characterized kaempferol toward chemoprevention.

13 ctiveness of antioxidants in prostate cancer chemoprevention.

14 iotic electrophiles is a strategy for cancer chemoprevention.

15 nesis and could serve as a unique target for chemoprevention.

16 is known about decisions of women regarding chemoprevention.

17 urcumin as a novel approach to breast cancer chemoprevention.

18 ke tamoxifen or raloxifene for breast cancer chemoprevention.

19 lped in defining the crucial role of NRF2 in chemoprevention.

20 han their conventional NSAID counterparts in chemoprevention.

21 ons on the use of 5-ARIs for prostate cancer chemoprevention.

22 nanotechnology for enhancing the outcome of chemoprevention.

23 tase inhibitors (5-ARIs) for prostate cancer chemoprevention.

24 s of compounds may have other effects beyond chemoprevention.

25 ing agents are in clinical trials for cancer chemoprevention.

26 on of this pathway is a potential target for chemoprevention.

27 ld affect strategies for early detection and chemoprevention.

28 vation of p53-dependent apoptosis during its chemoprevention.

29 eventive strategies, illustrating a need for chemoprevention.

30 c HBEC cells, suggesting their potential for chemoprevention.

31 ng these benefits against potential risks of chemoprevention.

32 rding the risk of malaria after cessation of chemoprevention.

33 be used to test therapeutic agents aimed at chemoprevention.

34 ugs (NSAIDs), and statins may play a role in chemoprevention.

35 otechnology to improve the outcome of cancer chemoprevention.

36 se the model for studies on pathogenesis and chemoprevention.

37 luding use of ACTs for malaria treatment and chemoprevention.

38 n botanic medicines for CTC-based metastatic chemoprevention.

39 may comprise targets for early treatment and chemoprevention.

40 it polyphenols have the potential for cancer chemoprevention.

41 ning and should provide novel approaches for chemoprevention.

42 tential utility of this natural compound for chemoprevention.

43 e markers as well as therapeutic targets for chemoprevention.

44 ce was significantly reduced in women taking chemoprevention (10-year cumulative risk: 7% with chemop

45 prevention (10-year cumulative risk: 7% with chemoprevention; 21% with no chemoprevention; P < .001).

46 revention must be re-evaluated and uptake of chemoprevention actively encouraged.

47 lmethane (DIM) has been known to have cancer chemoprevention activity.

48 toms may improve QOL and potentially improve chemoprevention adherence.

49 ith a strong rationale to use this agent for chemoprevention against DCIS.

50 ith a strong rationale to use this agent for chemoprevention against DCIS.Oncogene advance online pub

51 ents, and a systematic step-wise approach to chemoprevention agent development are all critical for m

52 ancer Institute's Phase I/II prostate cancer chemoprevention agent development program.

53 inally, 3,3'-Diindolylmethane (DIM), a known chemoprevention agent, is capable of suppressing PCGEM1

54 emerging field of cancer prevention through chemoprevention agents and cancer vaccines offers signif

55 and antitumor activities or can function as chemoprevention agents by preventing the metabolic activ

56 ng assay permits identification of potential chemoprevention agents in complex natural product mixtur

57 Chemoprevention agents might be used for average-risk as

58 ped to facilitate the discovery of potential chemoprevention agents that bind to human RXRalpha.

59 CRC chemoprevention agents that have been studied include as

60 Six chemoprevention agents were identified: tamoxifen, ralox

61 BRCA1 gene tend to lack targets for approved chemoprevention agents.

62 xamining active metabolites, and considering chemoprevention all translated through clinical trials t

63 ported to display strong efficacy for cancer chemoprevention, although their mechanism of action is p

64 Topical tretinoin has been used for KC chemoprevention, although this use is unproven.

65 ders are encouraged to discuss the option of chemoprevention among women at increased BC risk.

66 RXRs represent important targets for cancer chemoprevention, an ultrafiltration mass spectrometry-ba

67 hibitors are being used increasingly in both chemoprevention and adjuvant settings.

68 ase public awareness about the importance of chemoprevention and cancer preventive vaccines.

69 UGT genetic polymorphisms in carcinogenesis, chemoprevention and cancer risk.

70 rationale for targeting acetylated STAT3 for chemoprevention and cancer therapy.

71 uggest that TBE-31 should also be tested for chemoprevention and chemotherapy in relevant models of c

72 s in the development of Nrf2-based drugs for chemoprevention and chemotherapy.

73 nhibition of NOTCH signaling may improve CRC chemoprevention and chemotherapy.

74 be a target for overcoming the resistance to chemoprevention and chemotherapy.

75 years, providing a window of opportunity for chemoprevention and early intervention.

76 utic target for both squamous cell carcinoma chemoprevention and for the treatment of established tum

77 o investigate the mechanisms of prostacyclin chemoprevention and identify biomarkers for its use, we

78 l evaluation in deciding whether to initiate chemoprevention and in comparing the benefits and risks

79 taII is an important target for colon cancer chemoprevention and the PKCbeta-selective inhibitor enza

80 hways associated with ZEB1 are potential EMT chemoprevention and therapeutic targets in NSCLC.

81 at CDK2 is a useful molecular target for the chemoprevention and therapy against skin cancer.

82 at we believe to be a novel approach for CRC chemoprevention and therapy by increasing tumor glucocor

83 may be an important novel target for cancer chemoprevention and therapy by natural and synthetic ITC

84 ion opens up new opportunities for molecular chemoprevention and therapy of skin cancer by targeting

85 ticles is a promising new approach to cancer chemoprevention and therapy.

86 is element is a promising strategy of cancer chemoprevention and therapy.

87 SAMe and MTA may be attractive agents in the chemoprevention and treatment of colon cancer.

88 resent a suitable therapeutic option for the chemoprevention and treatment of Cowden disease patients

89 ective and safe therapeutic approach for the chemoprevention and treatment of human cholangiocarcinom

90 tracts have significant implications for the chemoprevention and treatment of prostate cancer and oth

91 t be used for CRC screening and modified for chemoprevention and treatment.

92 Vitamin D is a well-studied agent for cancer chemoprevention and treatment.

93 tality, and currently, there is no effective chemoprevention and treatment.

94 arcinoma cell growth and may be targeted for chemoprevention and treatment.

95 genetic models promise to reduce the risk of chemoprevention and ultimately to reduce the risk and bu

96 ly induced, making them ideal candidates for chemoprevention and/or chemotherapy in these cancers.

97 rs, suggesting a new target for liver cancer chemoprevention and/or chemotherapy.

98 s, is a strategy for cancer chemotherapy and chemoprevention, and 3-amino-6-(3'-aminopropyl)-5H-inden

99 s RP, and RP alone cannot be recommended for chemoprevention, and new, better agents are needed in th

100 r using selective COX-2 inhibitors in cancer chemoprevention, and outline new avenues of research int

101 ered survey, with updated items on genetics, chemoprevention, and survivorship, was mailed to a strat

102 women choosing surveillance, with or without chemoprevention, and those undergoing bilateral prophyla

103 pulation level, to clear infections, provide chemoprevention, and to reduce onward transmission of in

104 cidal nets and expansion of seasonal malaria chemoprevention; and a reduction in coverage to 2006-08

105 me these challenges, here we developed a new chemoprevention approach that specifically targets prema

106 The key principles of cancer chemoprevention are discussed and areas for improvement

107 Clinical trials for chemoprevention are involving more diverse regimens, fol

108 pirin in pain-relief, cardio-protection, and chemoprevention are well-known to result from the covale

109 rvention, the incidence of malaria in the no chemoprevention arm was 6.95 episodes per person-year at

110 hese studies have important implications for chemoprevention as well as therapy of common, mutant p53

111 levels while being effective in the in vivo chemoprevention assay.

112 emerged as the most likely NSAID for use in chemoprevention because of its known cardiovascular bene

113 Prostate cancer is an attractive target for chemoprevention because of its ubiquity, treatment-relat

114 Selenium chemoprevention by apoptosis has been well studied, but

115 esis may be an important mechanism in cancer chemoprevention by PEITC.

116 lly selective approach for colorectal cancer chemoprevention by targeting APC-deficient cells for apo

117 bserved 8 months later, suggesting potential chemoprevention by targeting CCN1-inhibitable EGFR-depen

118 nic widely used in breast cancer therapy and chemoprevention), by the immobilized enzyme.

119 In the year after the cessation of chemoprevention, children who were highly adherent to DP

120 ative studies involving patients enrolled in chemoprevention clinical trials, including chromosomal a

121 ker is now being prospectively integrated in chemoprevention clinical trials.

122 netics, risk modeling, molecular targets for chemoprevention, clinical prevention trials, behavioral

123 ria exposure, and lower in those adherent to chemoprevention compared to nonadherent children and tho

124 nda to determine whether 3 months of malaria chemoprevention could reduce morbidity and mortality aft

125 e plus amodiaquine used for seasonal malaria chemoprevention could reduce mortality and morbidity amo

126 information about hypothetical breast cancer chemoprevention decisions (mean uptake rate, 24.7%) and

127 ntimalarial agents used for seasonal malaria chemoprevention did not result in a lower incidence of d

128 However, the optimal chemoprevention drug and dosing strategy is unclear in a

129 Moreover, chemoprevention during early childhood prevented the dev

130 Despite great interest in cancer chemoprevention, effective agents are few.

131 of naturally occurring compounds with cancer chemoprevention effects that have become clinically avai

132 e establishing a new paradigm, combinatorial chemoprevention efficacy in familial adenomatous polypos

133 ent to infant and maternal care and possible chemoprevention (eg, aspirin therapy) to prevent preecla

134 Chemoprevention, especially through the use of naturally

135 llocatechin-3-gallate (EGCG) is a well-known chemoprevention factor.

136 ve been the focus of research in the dietary/chemoprevention field.

137 The concept of chemoprevention for the explicit benefit of the canine i

138 le support for the use of analgesic drugs as chemoprevention for this disease.

139 In this setting, effective antimalarial chemoprevention fostered the development of CD4(+) T cel

140 ents of readmission or death occurred in the chemoprevention group and 316 occurred in the placebo gr

141 went randomization; 524 were assigned to the chemoprevention group and 525 to the placebo group.

142 wer incidence of readmission or death in the chemoprevention group than in the placebo group was rest

143 d to receive dihydroartemisinin-piperaquine (chemoprevention group) or placebo, administered as 3-day

144 Children that received seasonal malaria chemoprevention had fewer malaria episodes and showed si

145 Seasonal malaria chemoprevention had no observable effect on fold changes

146 Cancer chemoprevention has many challenges to face but this onl

147 ement of duodenal neoplasia is difficult and chemoprevention has not been successful.

148 Despite significant progress, chemoprevention has not been widely adopted.

149 Our data suggest that seasonal malaria chemoprevention has the potential to avert several milli

150 molecular targets for effective colon cancer chemoprevention have been characterized and validated.

151 y potential targets for molecularly targeted chemoprevention, here we perform integrated cross-specie

152 breast cancer incidence in women opting for chemoprevention highlights the potential for risk reduct

153 t CEAs in the oncology literature, including chemoprevention in breast cancer, adjuvant endocrine the

154 ith the model that mesalamine contributes to chemoprevention in CAC by reducing beta-catenin signalin

155 roof-of-concept for a wholly new approach to chemoprevention in carriers of BRCA1 mutations as a stra

156 Chemoprevention in former smokers using the prostacyclin

157 eficial in addition to its potential for HCC chemoprevention in HCV-infected patients.

158 an effective biomarker of CAC or target for chemoprevention in patients with inflammatory bowel dise

159 gement of biliary tract dysplasia and cancer chemoprevention in PSC.

160 to be done to fully realize the potential of chemoprevention in this disease.

161 rolled in a randomized trial of antimalarial chemoprevention in Tororo, Uganda, an area of high trans

162 an open-label randomized controlled trial of chemoprevention in Ugandan children.

163 ase inhibitors are established breast cancer chemoprevention interventions.

164 Chemoprevention is a practical and translational approac

165 Prostate cancer chemoprevention is an alternative and potential strategy

166 However, the broad application of chemoprevention is compromised at present by limited eff

167 Chemoprevention is defined as nutritional or pharmaceuti

168 First we agreed that the term chemoprevention is inappropriate and suggested that the

169 If chemoprevention is to be adopted successfully, a holisti

170 hrough colonoscopic surveillance and aspirin chemoprevention; it also enables cascade testing of rela

171 ay courses of DP for either seasonal malaria chemoprevention, mass drug administration, or treatment

172 Antimalarial chemoprevention may affect this response by altering exp

173 uction of infections due to seasonal malaria chemoprevention may also prevent immune dysfunction.

174 pothetical uptake) or accepted (real uptake) chemoprevention medications.

175 r homeostasis, and cancer; new approaches in chemoprevention, molecular diagnostics and genetic testi

176 lled and 393 randomized at 6 mo of age to no chemoprevention, monthly sulfadoxine-pyrimethamine (SP),

177 a global issue, the opportunities offered by chemoprevention must be re-evaluated and uptake of chemo

178 roartemisinin-piperaquine (DP; n = 87) or no chemoprevention (n = 90) from 6 to 24 months of age, wit

179 ems and may lead to novel approaches for the chemoprevention of arsenic toxicity.

180 fene was approved in 2007 by the FDA for the chemoprevention of breast cancer in postmenopausal women

181 natural compound proposed for the treatment/chemoprevention of breast cancer.

182 terpenoid family as effective agents for the chemoprevention of CAC in humans.

183 esis in rat, supporting its potential use in chemoprevention of cancer.

184 metabolites, which are crucial for selenium chemoprevention of cancer.

185 rs may help define this axis as a target for chemoprevention of carcinomas.

186 These results suggest that effective chemoprevention of colon cancer by NSAIDs lies in the el

187 eas inhibitors of COX-2 could be of value in chemoprevention of colon cancer.

188 ROS and the mixture may be effective in the chemoprevention of colon cancer.

189 uch as prevention of venous thromboembolism, chemoprevention of colorectal (and other) cancers, and r

190 ory bowel disease, colorectal cancer and the chemoprevention of colorectal adenoma by influencing the

191 ty of GCC hormone replacement therapy in the chemoprevention of colorectal cancer progression.

192 n and signalling represent valid targets for chemoprevention of colorectal cancer.

193 We review the prospect of chemoprevention of CRC, results from preclinical and hum

194 elective COX-2 inhibitors limit their use in chemoprevention of CRC.

195 ional strategies for risk stratification and chemoprevention of gastric cancer are needed.

196 ion are potent natural dietary compounds for chemoprevention of gastrointestinal cancers.

197 in signaling pathway and may be a target for chemoprevention of HCC.

198 findings may have clinical implications for chemoprevention of hepatocellular carcinoma in the cirrh

199 is pathway may be an attractive approach for chemoprevention of hepatocellular carcinoma.

200 RATIONALE: Improving the early detection and chemoprevention of lung cancer are key to improving outc

201 NF-kappaB pathway as a potential target for chemoprevention of lung cancer.

202 STAT3 is a potential target for chemoprevention of melanoma.

203 , and selection of dose in the treatment and chemoprevention of neurodegenerative disease.

204 ept for regular sunscreen use, the quest for chemoprevention of NMSC in the general population has be

205 Evolving areas include chemoprevention of post-endoscopic retrograde cholangiop

206 Chemoprevention of post-endoscopic retrograde cholangiop

207 me may be incorporated into regimens for the chemoprevention of skin cancers.

208 y may be an important molecular mechanism in chemoprevention of squamous cell carcinoma by sulforapha

209 In addition, the potential cancer chemoprevention of the secondary metabolites (phenolic e

210 icinal herbs holds exciting promises for the chemoprevention of this disease.

211 Chemoprevention offers a promising strategy for preventi

212 urrent study, the impact of seasonal malaria chemoprevention on malaria-induced immune dysfunction, a

213 diagnosed at early stages offering a unique chemoprevention opportunity.

214 crophages during tumor formation may lead to chemoprevention options for at-risk obese women.

215 nsidered for investigation as a strategy for chemoprevention or additional therapy of early HCC in pa

216 is imperative in targeting this pathway for chemoprevention or chemotherapy.

217 o achieve either goal, with seasonal malaria chemoprevention or indoor residual spraying added second

218 ACF that may provide new targets for cancer chemoprevention or lead to the development of new biomar

219 uld help identify women who may benefit from chemoprevention or more screening.

220 t and similar between children randomized to chemoprevention or no chemoprevention.

221 tection of lung cancer and novel targets for chemoprevention or therapy.

222 inflammatory drugs (NSAIDs) are effective in chemoprevention or treatment of cancer.

223 common cancer worldwide that lacks effective chemoprevention or treatment.

224 the subpopulations for which the benefits of chemoprevention outweigh the risks of adverse side-effec

225 a incidence as compared to children given no chemoprevention (P = .004).

226 e risk: 7% with chemoprevention; 21% with no chemoprevention; P < .001).

227 andomly assigned to receive seasonal malaria chemoprevention plus either azithromycin (9735 children)

228 Seasonal malaria chemoprevention, previously known as intermittent preven

229 In malaria-endemic regions, antimalarial chemoprevention protects long after its cessation and as

230 Chemoprevention provides an opportunity to complement sc

231 itor the efficacy of antiangiogenic drugs or chemoprevention regimens targeting the vasculature in pr

232 ll hopefully streamline head and neck cancer chemoprevention research.

233 nt development are all critical for melanoma chemoprevention research.

234 ed access to risk-reducing behaviors such as chemoprevention, screening, and follow-up of abnormal te

235 It is unclear whether chemoprevention similarly enhances immunity following na

236 have reanalyzed 2 trials of seasonal malaria chemoprevention (SMC) in Bousse, Burkina Faso, and Kati,

237 Seasonal malaria chemoprevention (SMC) is a novel strategy to reduce mala

238 Seasonal malaria chemoprevention (SMC) is now widely deployed in the Sahe

239 Seasonal malaria chemoprevention (SMC) is recommended in the Sahel region

240 Seasonal malaria chemoprevention (SMC) with amodiaquine and sulfadoxine-p

241 Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP

242 ced the incidence of and mortality from CRC, chemoprevention strategies have the potential to further

243 of action, and the potential for combination chemoprevention strategies that involve tea as well as o

244 er the past 30 years, there are no effective chemoprevention strategies, and only one systemic therap

245 implications for dietary recommendations and chemoprevention strategies.

246 This study aimed at a targeted chemoprevention strategy for BRCA1-associated malignanci

247 ggests that c-Myc inhibition may be a viable chemoprevention strategy for colorectal cancer.

248 investigate the efficacy of a combinatorial chemoprevention strategy for esophageal adenocarcinoma a

249 This chemoprevention strategy has important implications for

250 roviding a previously undescribed epigenetic chemoprevention strategy in which cells with LOI are "IG

251 research includes numerous large and smaller chemoprevention studies of nutritional supplements, othe

252 results indicate that COX-2 is an important chemoprevention target and that inhibition of this enzym

253 in TRAMP mice, suggesting NOX as a potential chemoprevention target in controlling PCa.

254 e lysophosphatidic acid pathway as a central chemoprevention target.

255 llowing Apc-loss and constitutes a potential chemoprevention target.

256 ium falciparum sporozoites administered with chemoprevention targeting blood-stage parasites results

257 ay be good for safe and effective metastatic chemoprevention targeting circulating tumor cells (CTC).

258 on factor NF-E2-related factor-2 (NRF2), are chemoprevention targets because of their role in regulat

259 retinal to retinoic acid, could benefit from chemoprevention therapy.

260 fic QOL influence a woman's decision to stop chemoprevention therapy.

261 that in areas suitable for seasonal malaria chemoprevention, there are 39 million children under 5 y

262 ing the rationale for using Nrf2 inducers in chemoprevention, this antioxidative transcription factor

263 Like earlier efforts at chemoprevention, this study failed to show therapeutic b

264 years old) who participated in a prospective chemoprevention trial (of vitamin D and calcium) from 20

265 This large chemoprevention trial did not establish the equivalence

266 ly in Ugandan children enrolled in a malaria chemoprevention trial from 6 to 36 months of age.

267 f CRA in 267 participants of a phase IIb/III chemoprevention trial of DFMO/sulindac.

268 andomized Veterans Affairs Topical Tretinoin Chemoprevention Trial of high-dose topical tretinoin for

269 The Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial was a randomized clinical trial of

270 C) in the Veterans Affairs topical tretinoin chemoprevention trial, which included individuals with a

271 g they are ideal candidates for inclusion in chemoprevention trials and require surveillance by perio

272 n data set included participants involved in chemoprevention trials at the British Columbia Cancer Ag

273 Two chemoprevention trials found that supplementation with b

274 e preclinical studies and cardiovascular and chemoprevention trials have raised concerns that high fo

275 cular attention paid to the results of major chemoprevention trials involving selenium supplementatio

276 d provides an important rationale for future chemoprevention trials of head and neck and lung cancers

277 ividuals for lung cancer in surveillance and chemoprevention trials.

278 ritis and are currently under study in human chemoprevention trials.

279 Breast cancer chemoprevention uptake rates are low and variation is wi

280 Cancer chemoprevention uses natural, synthetic, or biological s

281 taII is an effective target for colon cancer chemoprevention using enzastaurin (LY317615), a PKCbeta-

282 Chemoprevention using nanotechnology to improve the bioa

283 The Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) trial was a randomized, double-b

284 ns in the Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Trial.

285 they have started to be implicated in cancer chemoprevention, via the targeting of reversible epigene

286 In this context, chemoprevention was achieved by using the mammalian targ

287 Chemoprevention was stopped at 24 mo of age, and partici

288 In multivariable analysis, chemoprevention was the only clinical factor associated

289 To explore a molecular mechanism of chemoprevention, we examined the effect of mesalamine on

290 mized controlled trial of colorectal adenoma chemoprevention, we tested whether 1000 IU/day vitamin D

291 ressed patient decisions about breast cancer chemoprevention, were published in 1995 or later, were p

292 ement of severe disease and seasonal malaria chemoprevention where recommended for both Accelerate sc

293 ition may be a promising strategy for cancer chemoprevention with lack of the adverse cardiovascular

294 nsmission, 3 months of postdischarge malaria chemoprevention with monthly dihydroartemisinin-piperaqu

295 benefit/risk index to quantify benefits from chemoprevention with tamoxifen or raloxifene.

296 feasibility of targeting mPGES-1 for cancer chemoprevention with the potential for improved tolerabi

297 bona fide target for effective combinatorial chemoprevention with Urso and Aspirin.

298 o delay, prevent or reverse carcinogenesis ('chemoprevention') with the ultimate goal of reducing can

299 HuR inhibition as an effective means of FAP chemoprevention, with caution advised in the setting of

300 laria burden in areas where seasonal malaria chemoprevention would be appropriate.